RNAi Drug Delivery Market

RNAi Drug Delivery Market Overview

The global RNAi drug delivery market, valued at USD 103.23 billion in 2024, is projected to reach USD 134.0 billion in 2025 and USD 818.45 billion by 2035, representing a CAGR of 19.8% during the forecast period.

To learn more about this report, request a free sample copy

With successful approval of RNA therapeutics, the market for RNAi drug delivery is consistently gaining traction. Notably, RNA based therapeutics are susceptible to degradation due to poor stability and low cellular uptake. Owing to the poor stability, these therapeutic drugs require specialized RNAi drug delivery system that enable targeted delivery and enhance bioavailability of the drugs for gene silencing.

RNAi drug delivery system, such as lipids, nanoparticles and nucleic acids leverage RNAi (RNA interference) process to deliver RNAi therapeutics at targeted sites with higher efficacy. To date, several advancements have been made in RNAi therapeutics and technology to improve efficacy and target delivery capabilities.

Currently, the market players are focusing on advancements in nanotechnology, which is likely to be a key growth factor for the market. Additionally, the growing shift towards personalized therapies and RNA based therapeutics has further fueled the demand for RNAi drug delivery systems. In March 2025, Sanofi received FDA approval for its RNAi therapeutic Qfitlia for use in patients with hemophilia A or B with or without inhibitors. This drug uses Alnylam Therapeutics’ ESC-GalNAc Conjugate Technology for subcutaneous administration of the drugs and targeted delivery to the liver.

A recent study published by researchers at the University of Toronto in October 2024 highlighted lipid nanoparticles manufacturing that quickly degrade in the body without altering drug efficacy. Given the ongoing initiatives, several industrial players have shown active interest in this field to drive the development of advanced RNAi drug delivery systems.

It is worth noting that several companies are focusing on the research initiatives on RNAi drug delivery. Driven by the ongoing initiatives and rapid demand for RNAi technologies for drug delivery, we believe that the market for RNAi drug delivery platforms and technologies is expected to grow at a higher rate during the forecast period.

RNAi Drug Delivery Market Segmentation Insights

The market report provides comprehensive information on industrial players who are currently active across various segments of the industry as mentioned in the table below.

RNAi Drug Delivery Market: Report Attributes / Market Segmentation

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 134.0 Billion
Market Size 2035	USD 818.45 Billion
CAGR till 2035	19.8%
Type of Technology	siRNA miRNA shRNA Others
Type of Target Disease	Cancer Viral Infections Genetic Disorders Metabolic Diseases Other Diseases
Type of Delivery System	Nanoparticle Drug Delivery Technology Pulmonary Drug Delivery Technology Nucleic Acid Drug Delivery Technology Aptamer Drug Delivery Technology
Type of Targeted Tissue	Liver Lungs Brain Heart Others
Route of Administration	Intravenous Intramuscular Subcutaneous Local Injection Oral
End User	Pharmaceutical Companies Biotechnology Companies Contract Research Organizations (CROs) Academic and Research Institutions Government and Regulatory Bodies
Geographical Regions	North America (US, Canada, Mexico) Europe (France, Germany, Italy, Spain, UK and Rest of Europe) Asia-Pacific (China, India, Japan, South Korea, and Rest of Asia-Pacific) Middle East and North Africa (Egypt, Saudi Arabia and United Arab Emirates) Latin America (Argentina and Brazil)
Key Companies Profiled	Alnylam Pharmaceuticals Arrowhead Pharmaceuticals Arcturus Therapeutics Bayer BioNTech Dicerna Pharmaceuticals Ionis Pharmaceuticals Moderna Therapeutics Novartis Pfizer Roche Regeneron Pharmaceuticals Sanofi Takeda Pharmaceutical Viridian Therapeutics (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

One of the key objectives of the RNAi drug delivery market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of technology (siRNA, miRNA, shRNA and others), type of target disease (cancer, viral infections, genetic disorders, metabolic diseases and other diseases), type of delivery system (nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology), type of targeted tissue (liver, lungs, brain, heart and others), route of administration (intravenous, intramuscular, subcutaneous, local injection and oral), end user (pharmaceutical companies, biotechnology companies, contract research organizations (CROs), academic and research institutions and government and regulatory bodies), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three RNAi drug delivery market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.

RNAi Drug Delivery Market Share Insights

Market Share by Type of Technology

Based on the type of technology, the global market is segmented into siRNA, miRNA, shRNA and others. According to our RNAi drug delivery market report, presently siRNA segment accounts for the largest share of the market. This can be attributed to the increasing demand for siRNA-based therapeutics to treat viral infection and cancer. Notably, these therapeutics require advanced siRNA based drug delivery system for targeted delivery of the drug, which is expected to be a key reason for highest share.

It is worth mentioning that miRNA segment is expected to grow at a substantial CAGR during the forecast period. Notably, miRNA plays a significant role in gene expression and silencing. Hence, the growing understanding about miRNA as targeted drug delivery technologies is likely to drive its demand during the forecast period.

Market Share by Target Disease

This segment highlights the distribution of global market across different disease areas, such as cancer, viral infections, genetic disorders, metabolic diseases and other diseases. According to our RNAi drug delivery market analysis report, currently cancer segment holds the highest share of the market. This is potentially due to the rising adoption of RNA based therapies and RNAi based therapeutics to treat patients with cancer specifically associated with gene regulations.

Interestingly, in the future viral infections segment is likely to register a higher CAGR during the forecast period. This can be attributed to the growing prevalence of viral diseases, such as HIV, COVID and influenza that necessitated the demand for advanced RNA based vaccines. Thus, heightened demand for RNA based therapeutics has further underscored the requirement for RNAi based drug delivery systems.

Market Share by Type of Delivery System

On the basis of delivery system, the global market is segmented into nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology. Presently, nanoparticles drug delivery technology accounts for the largest share of the RNAi drug delivery market size. This can be attributed to the growing focus on nanoparticles, such as lipid nanoparticles to enhance drug stability and cellular uptake. Driven by the ongoing focus, this segment is expected to register a higher CAGR during the forecast period.

Market Share by Type of Targeted Tissue

The global market is further categorized across different types of targeted tissue, such as liver, lungs, brain, heart and others. According to our RNAi drug delivery market report, presently the liver segment accounts for the highest share (over 25%) of the market. This dominance is likely to be the result of growing incidence of liver diseases, such as hepatitis B and C. Notably, the USFDA has approved RNAi therapeutics that utilize small interfering RNA (siRNA) for silencing genes to treat liver associated diseases has further bolstered the demand for advanced RNAi based drug delivery systems. Additionally, the expanding research on advanced therapies to treat liver disease is likely to grow this segment at a higher CAGR during the forecast period.

Market Share by Route of Administration

Based on the route of administration, the global market is segmented into intravenous, intramuscular, subcutaneous, local injection and oral. According to our market analysis, intravenous segment holds the highest share of the market for RNAi drug delivery. This can be attributed to the fact that intravenous administration enhances the target efficacy. Furthermore, intravenous administration helps to overcome the systemic delivery limitations. Driven by the growing preference, this segment is likely to maintain dominance and is poised to grow at a higher CAGR during the forecast period.

Market Share by End User

The global market is distributed across different end users, such as pharmaceutical companies, biotechnology companies, contract research organizations (CROs), academic and research institutions and government and regulatory bodies. According to RNAi drug delivery market analysis, presently, pharmaceutical companies account for the highest share of the market. This can be attributed to the fact that pharmaceutical companies are focusing on research, development and commercialization of RNAi based therapeutics, which is expected to the growing demand for RNAi drug delivery systems.

However, in the long run, it is expected that pharmaceutical and biotechnology company’s segment are expected to grow at a higher CAGR during the forecast period. This can be attributed to the rising drug development activities and focus on drug innovations.

Market Share by Geographical Regions

Based on the geographical regions, the global market is distributed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Among these, presently North America accounts for the highest share (43%) of the market. This dominance is due to the rising incidence of chronic diseases that require advanced RNAis based therapeutics to treat patients. These RNAi based therapeutics require specialized drug delivery technologies, such as nanoparticle drug delivery technology, pulmonary drug delivery technology, and aptamer drug delivery technologies. Additionally, the expanding research on advanced RNAi based therapies has further raised the demand for RNAi drug delivery systems in this region.

In Asia-Pacific, the market is expected to grow at a substantial CAGR during the forecast period. This lucrative growth is driven by the rising shift towards personalized medicine that require specialized drug delivery systems to improve drug stability and efficacy at targeted sites.

RNAi Drug Delivery Market Dynamic Insights

The “RNAi Drug Delivery Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for RNAi drug delivery industrial players. Key takeaways of the market report are briefly discussed below.

RNAi Drug Delivery Market Competitive Landscape

Currently, the market landscape is witnessing the presence of several well-established and new entrants. Majority of these industrial players are focusing on technological advancements, such as adoption of nanotechnology for faster drug delivery and undertaking strategic initiatives to develop next generation RNAi drug delivery technology. Overall, the market is highly consolidated with the presence of several small, mid-sized and large industrial players.

RNAi Drug Delivery Market Drivers: Increasing Prevalence of Chronic Diseases and Demand for RNAi Drug Delivery Systems for Cancer Therapy

Some of the notable drivers that are propelling the market includes, rising incidence of chronic diseases and heightened requirement of targeted drug delivery mechanisms. It is worth noting that the rising prevalence of diseases, such as cardiovascular diseases, cancer, genetic diseases and neurological disorders has necessitated the demand for advanced personalized therapies specifically RNAi-based drugs that require specialized RNAi drug delivery systems for target efficacy. Additionally, the expanding research on advancing RNAi technology for more efficient and safe delivery systems has contributed to the growth of market.

RNAi Drug Delivery Market Challenges: Off-Target Effect, Complex Manufacturing Process and Degradation

Several factors that are impeding the market growth includes off-target effects, complex manufacturing process and faster degradation of RNAi molecules. Notably, the RNAi molecules can bind to unintended mRNA sequence which may lead to silencing of off-target genes, thereby causing off-target effects.

Further, naked RNA molecules can easily degrade by the presence of ubiquitous nucleases present in the tissue and blood, therefore limiting the therapeutic efficiency. In addition, stringent guidelines and complexity associated with manufacturing process may delay the development and approval process of the drugs delivery technologies.

RNAi Drug Delivery Market Trends: Technological Advancements and Expanding Research for Advanced RNAi Drug Delivery for Metabolic Diseases

The current focus of industrial players is on advancements in lipid nanoparticles technology that has played a significant role in successful delivery of RNAi therapeutics. Considering its significances in targeted drug delivery device, market players are aiming to develop targeted lipid nanoparticles with ligands, such as antibodies and peptides to improve drug stability.

Additionally, the market players are aiming to develop next-generation lipid formulations and non-lipid nanoparticle drug delivery systems, such as polymer nanoparticles, peptide-based delivery systems and antibody-RNA conjugates. These factors are collectively offering enormous opportunities to industrial players for innovations.

RNAi Drug Delivery Market Size Analysis

Currently, the market for RNAi drug delivery is estimated to be valued at USD 134.00 billion and is projected to reach USD 818.45 billion by 2035, representing a CAGR of 19.8% during the forecast period. With growing approval of RNAi therapeutics and heightened demand for advanced drug delivery systems, this market is anticipated to grow steadily during the forecast period. Notably, several market players are focusing on strategic initiatives to develop advanced nanoparticles for drug delivery. For instance, in May 2024, Aldevron announced its strategic partnership with Acuitas Therapeutics to expand its capabilities in mRNA LNP encapsulation by incorporating proprietary LNP encapsulation platform.

Leading Companies in RNAi Drug Delivery Market

Examples of key players engaged in this domain (which have also been captured in this report) include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Arcturus Therapeutics, Bayer, BioNTech, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, Moderna Therapeutics, Novartis, Pfizer, Roche, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical and Viridian Therapeutics. This market report includes an easily searchable excel database of all the companies focusing on the development of platforms, technologies or devices for RNAi drug delivery.

RNAi Drug Delivery Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain across different segments. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report, RNAi Drug Delivery Market, 2020-2024 (Historical Trends), and Future Forecast till 2035 (Forecasted Estimates).
• An outline of the systematic research methodology adopted to conduct the study on the market analysis, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure the accuracy and reliability of our findings.
• An overview of economic factors that impact the RNAi drug delivery market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the insights captured during our research. It offers a high-level view of the current state of the RNAi drug delivery industry and its evolution in the mid-and long-term.
• A detailed assessment of the market landscape is based on several relevant parameters, including years of experience, company size, headquarters location, and ownership structure.
• Elaborated profiles of prominent players engaged in offering platforms or technologies for RNAi drug delivery, featuring information on their year of establishment, location of headquarters, company size, company mission, company footprint, management team, contact details, financial information, operating business segments, RNAi drug delivery product portfolio, recent developments, and an informed future outlook.
• A discussion on affiliated trends, key drivers, and challenges under a SWOT framework, which is likely to impact the industry's evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall RNAi drug delivery industry.
• A market impact analysis features a discussion on the factors that can impact the RNAi drug delivery market growth.
• A detailed estimate of the current market size and the future growth potential of the market trends over the next decade. Based on multiple parameters, we have provided an informed estimate of the market's evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunities within the RNAi drug delivery industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current and future RNAi drug delivery market size across various types of technology, including siRNA, miRNA, shRNA and Others.
• Detailed projections of the current and future market for RNAi drug delivery platforms and technologies across various types of target disease, including cancer, viral infections, genetic disorders, metabolic diseases and other diseases.
• Detailed projections of the current and future market for RNAi drug delivery across various types of delivery system, including nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology.
• Detailed projections of the current and future RNAi drug delivery market size across various types of targeted tissue, including liver, lungs, brain, heart and others.
• Detailed projections of the current and future RNAi drug delivery industry size across various route of administration, including intravenous, intramuscular, subcutaneous, local injection and oral.
• Detailed projections of the current and future RNAi drug delivery market across various end users, including pharmaceutical companies, biotechnology companies, contract research organizations (CROs), academic and research institutions and government and regulatory bodies.
• Detailed projections of the current and future market for RNAi drug delivery across various geographical regions, such as North America (US, Canada and Mexico), Europe (France, Germany, Italy, Spain, UK and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, and Rest of the Asia-Pacific), Middle East and North Africa (Egypt, Saudi Arabia and UAE), and Latin America (Argentina and Brazil).

Recent Developments in RNAi Drug Delivery Market

Several recent developments have taken place in the field of RNAi drug delivery. We have outlined some of these recent initiatives below.

• In April 2025, Silexion Therapeutics partnered with Catalent to advance the development of SIL204 formulation for both systemic as well as intratumoral delivery of their KRAS-targeting RNAi therapy.
• In December 2024, researchers of the University of Melbourne from the Caruso Nanoengineering Group created an advanced drug delivery system that is made with a coordination network of metal ions and biomolecules. This drug delivery system eliminates the requirement for complicated drug carriers, making it an ideal drug delivery system for a variety of applications.
• In October 2024, Assistant professor Keisuke Ueda from the Graduate School of Pharmaceutical Sciences introduced an innovative approach to increase siRNA-loaded LNPs by leveraging NMR-guided optimization of lipid nanoparticles to increase siRNA drug delivery.
• In July 2024, Aptamer Group announced a strategic partnership agreement with AstraZeneca to evaluate the optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA. Under this collaborative agreement, AstraZeneca will provide an siRNA for trial with optimer-based delivery vehicle of Aptamer’s for fibrotic liver cells.